| Revenue growth | 1% YoY for FY26; 36% YoY for Q4FY26. |
|---|---|
| Margins | EBITDA margins fell from 36.1% (FY25) to 32.0% (FY26). |
| Demand visibility | Customers deferred purchases due to macro headwinds; expecting recovery in FY27. |
| Management confidence | High for long-term growth as pilot trials transition to commercial phase. |
Growth
Q4FY26 revenue surged 36% YoY; however, full-year FY26 revenue grew only 1% while EBITDA margins contracted to 32%.
Outlook
Block 7 expansion commissioning in Q2FY27; ₹15cr FY26 capex for R&D/manufacturing. Dahej land acquired for large-scale projects.
Risks
Slowdown in Europe, geopolitical uncertainty, and raw material price volatility impacted margins and deferred customer purchases.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹717.35
- Market cap
- ₹920.9 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 59.7×Sector 47.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies Limited has issued the notice for its 31st Annual General Meeting scheduled for September 12, 2026. Shareholders will consider key resolutions and director appointments.
Shree Ganesh Remedies Annual Report
Shree Ganesh Remedies Limited has filed its Annual Report for FY 2025-26. It also includes the notice for the 31st Annual General Meeting on September 12, 2026.
Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies Results Update
Shree Ganesh Remedies announced its Q1FY27 financial results. Revenue from operations stood at ₹14.36 Crore, with a PAT of ₹1.12 Crore.
- Value
- ₹14.36 Cr
Shree Ganesh Remedies Other Announcement
Shree Ganesh Remedies Limited has appointed M/s. M. I. Prajapati & Associates LLP as the company's Cost Auditor for a term of 12 months.
- Execution
- 12 months